---
schema_version: "secwatch.filing_event.v1"
accession: "0001552000-22-000040"
form_type: "8-K"
ticker: "MPLX"
cik: "0001552000"
company_name: "MPLX LP"
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:23:10.366714+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MPLX CEO Hennigan reports no sign of cancer after treatment

## Summary
- CEO Michael Hennigan says tests show no sign of throat cancer following treatment.
- Completed seven-week radiation and chemotherapy protocol a few months ago.
- Prognosis is excellent; he will continue to be monitored as a routine precaution.
- Hennigan remains Chairman, President and CEO and is focused on leading MPLX.

## SEC filing metadata
- accession: 0001552000-22-000040
- form_type: 8-K
- ticker: MPLX
- cik: 0001552000
- company_name: MPLX LP
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/0001552000-22-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/mplx-20221011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001552000-22-000040
- JSON: https://secwatch.observer/filing/0001552000-22-000040.json
- Plain text: https://secwatch.observer/filing/0001552000-22-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.